AstraZeneca's Tagrisso plus chemotherapy wins EU approval for NSCLC [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
cancer (NSCLC) patients with epidermal growth factor receptor mutations (EGFRm) in adults. The tyrosine kinase inhibitor has been approved alongside pemetrexed and platinum-based chemotherapy for the first-line treatment of adults whose tumours have exon 19 deletions or exon 21 (L858R) mutations. Approval is based on positive data from the Phase III FLAURA2 trial (NCT04035486). The trial enrolled 557 patients, showing that Tagrisso and chemotherapy reduced the risk of disease progression or death by 38% by investigator assessment compared to Tagrisso monotherapy, which is the first-line global standard of care. Additionally, median progression-free survival was 25.5 months for patients treated with Tagrisso plus chemotherapy, an 8.8-month improvement versus monotherapy. Progression-free survival (PFS) results from a blinded independent central review (BICR) were consistent with the results by investigator assessment, showing 29.4 months median PFS with Tagrisso plus chemothera
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Resolution scores $83m to develop macrophage cell therapies [Yahoo! Finance]Yahoo! Finance
- AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use [Yahoo! Finance]Yahoo! Finance
- Owkin and AstraZeneca to develop AI tool for breast cancer testing [Yahoo! Finance]Yahoo! Finance
- CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphomaBusiness Wire
- Arcus and AstraZeneca enter trial collaboration for renal cancer treatment [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 10/1/24 - Form 6-K
- 9/26/24 - Form 6-K
- 9/23/24 - Form 6-K
- AZN's page on the SEC website